Gandeeva Therapeutics
Vancouver, United States· Est.
AI‑driven cryo‑EM platform creates molecular glues for oncology targets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
AI‑driven cryo‑EM platform creates molecular glues for oncology targets.
Oncology
Technology Platform
A proprietary AI‑cryo‑EM workflow that identifies transient protein interfaces, visualizes them at atomic resolution, and designs molecular glues or degraders to modulate those interactions.
Opportunities
Successful IND filings and early clinical data could unlock licensing or co‑development deals with large pharma, while the AI‑cryo‑EM platform can be offered as a service to external partners.
Risk Factors
High R&D cost, dependence on cryo‑EM throughput, and uncertainty in translating structural hits into safe, efficacious therapeutics pose significant execution risks.
Competitive Landscape
Competes with molecular‑glue companies (Arvinas, Nurix) and AI‑driven discovery firms; differentiation stems from its cryo‑EM‑validated design pipeline that may improve selectivity and reduce attrition.